For people living with dementia, support changes everything. The Alzheimer Society connects Albertans to dementia-friendly support, knowledge, and community.
January 02, 2024 13:17 ET
|
Alzheimer Society of Alberta and NWT
Edmonton, Jan. 02, 2024 (GLOBE NEWSWIRE) -- A diagnosis of dementia is not easy. During National Alzheimer’s Awareness Month in January, the ALZHEIMER SOCIETY OF ALBERTA AND NORTHWEST TERRITORIES...
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
December 04, 2023 07:09 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Neurological Biomarkers Research Report 2023: A Global $18.75 Billion Market by 2030 with Pipeline Analysis of Alzheimer's, Parkinson's, Multiple Sclerosis, & Autism Spectrum Disorder
November 14, 2023 05:28 ET
|
Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), By Type,...
Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults
October 30, 2023 08:30 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Phase 1a Clinical Data Presented at Clinical Trials on Alzheimer's Disease Meeting Support Continued Clinical Development
Allyx Therapeutics to Present Phase 1 Data for Lead Compound ALX-001 at the 16th Clinical Trials on Alzheimer's Disease Meeting
October 19, 2023 16:05 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics presents Phase 1 ALX-001 data at CTAD. ALX-001 is a small molecule with unique mechanism at mGluR5 to protect and preserve synapses.
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
September 06, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal...
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
August 17, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
BIOXCEL THERAPEUTICS, INC. INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
July 18, 2023 16:07 ET
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of persons and entities that purchased or acquired securities...
Global Immunoassay for Neurological Biomarkers Market to 2030: Increasing Prevalence of Neurological Diseases Fuels the Sector
June 05, 2023 05:08 ET
|
Research and Markets
Dublin, June 05, 2023 (GLOBE NEWSWIRE) -- The "Immunoassay for Neurological Biomarkers Market Size, Share & Trends Analysis Report By Product, By Disease (Alzheimer's Disease, Parkinson's...
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
April 20, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab...